Related Experiment Video
Updated: Jul 24, 2025
08:27
A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine
Published on: December 6, 2024
326
New Alternative? Self-Assembling Peptide in Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis
Banreet Singh Dhindsa1, Kyaw Min Tun2, Kyle J Scholten3
1Division of Gastroenterology and Hepatology, University of Nebraska Medical Center, 982000 Nebraska Medical Center, Omaha, NE, 68198-2000, USA.
Digestive Diseases and Sciences
|July 4, 2023
Summary
Self-assembling peptide (SAP) gel is a safe and effective endoscopic treatment for gastrointestinal bleeding (GIB), achieving 93.1% hemostasis. This innovative therapy shows promise for managing GIB with minimal adverse events.
Area of Science:
- Gastroenterology
- Biomaterials Science
Background:
- Gastrointestinal bleeding (GIB) is a significant cause of mortality, necessitating effective endoscopic treatments.
- Traditional endoscopic therapies include mechanical, thermal, and injection methods.
- Self-assembling peptide (SAP) gel presents a novel hemostatic agent for GIB management.
Approach:
- A systematic review and meta-analysis was conducted, searching major databases up to November 2022.
- Included 7 studies with 427 patients, analyzing hemostasis success, rebleeding, and adverse events.
- Employed random-effects models to calculate pooled estimates and 95% confidence intervals.
Key Points:
- SAP application was technically successful in all patients, including 34% on anticoagulation/antiplatelet agents.
- Pooled successful hemostasis rate was 93.1% (95% CI 84.7-97.0).
- Rebleeding rates were 8.9% (95% CI 5.3-14.4), with no SAP-related adverse events observed.
Conclusions:
- Self-assembling peptide (SAP) demonstrates safety and efficacy as an endoscopic treatment for GIB.
- SAP offers improved visualization compared to spray-based modalities.
- Further prospective or randomized controlled trials are warranted to validate these findings.
Related Concept Videos
01:26Peptic Ulcer Disease IV: Management
113
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
113
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
507
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
507
01:30Peptic Ulcer Disease I: Introduction
213
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
213
01:28Peptic Ulcer Disease II: Pathophysiology
552
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
552
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
644
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
644
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
468
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
468